Pharming Group (NASDAQ:PHAR - Get Free Report) was the recipient of a significant increase in short interest in December. As of December 31st, there was short interest totalling 25,900 shares, an increase of 149.0% from the December 15th total of 10,400 shares. Based on an average trading volume of 6,700 shares, the days-to-cover ratio is presently 3.9 days.
Wall Street Analyst Weigh In
PHAR has been the topic of several recent research reports. Oppenheimer decreased their price target on shares of Pharming Group from $31.00 to $30.00 and set an "outperform" rating on the stock in a research report on Monday, October 28th. Jefferies Financial Group initiated coverage on Pharming Group in a report on Monday, December 9th. They set a "buy" rating and a $14.00 target price for the company. Finally, HC Wainwright reissued a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research note on Tuesday, December 17th.
Get Our Latest Report on Pharming Group
Pharming Group Stock Up 6.0 %
PHAR traded up $0.56 on Tuesday, reaching $9.93. 1,921 shares of the company traded hands, compared to its average volume of 4,778. The company has a market cap of $673.60 million, a price-to-earnings ratio of -38.19 and a beta of -0.08. The company has a debt-to-equity ratio of 0.41, a current ratio of 3.53 and a quick ratio of 2.76. The stock's 50 day moving average price is $8.76 and its 200-day moving average price is $8.36. Pharming Group has a 52-week low of $6.65 and a 52-week high of $13.20.
Hedge Funds Weigh In On Pharming Group
A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its stake in Pharming Group (NASDAQ:PHAR - Free Report) by 75.4% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 41,110 shares of the company's stock after acquiring an additional 17,675 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.06% of Pharming Group worth $339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 0.03% of the company's stock.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
